Aurinia Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 28, 2022, reports on the financial results for the quarter and full year ended December 31, 2021. The filing serves as a current report to announce these results and incorporates a press release (Exhibit 99.1) by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1) and are not explicitly stated in the body of this 8-K filing.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the announcement of the fourth quarter and full-year 2021 results.
Guidance, Outlook, and Risks
The filing references "Company Updates" in the attached press release but does not detail specific guidance, outlook, management commentary, risks, or contingencies within the 8-K text itself. The document includes standard legal disclaimers stating that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2021.
- Verify the details of the "Company Updates" mentioned in the press release title for potential pipeline or operational changes.
- Confirm the exact date of the press release (February 28, 2022) to ensure alignment with the reporting period.
- Note that the 8-K text itself contains no financial data and relies entirely on the attached exhibit for quantitative analysis.